Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
MaxVision Biosciences is a private life science tools company focused on pathology research reagents and immunofluorescence and immunohistochemistry detection systems. The company appears to sell research-use products rather than develop therapeutic drug candidates, with offerings including MaxFluor, MaxFL, MaxSAB, double or triple staining detection systems, primary antibodies, tissue microarrays, chromogens, mounting media, and related reagents. Public business registry data indicates the company is an active Washington corporation, while commercial databases describe it as founded around 2010-2011 and operating from the Seattle-area/Kenmore-Bothell region. Based on the available evidence, MaxVision Biosciences is best characterized as a small, commercial-stage provider of pathology and immunostaining research products serving academic and laboratory customers.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on MaxVision Biosciences.